Astria Therapeutics (NASDAQ:ATXS) Shares Up 6%

Astria Therapeutics, Inc. (NASDAQ:ATXS)’s stock price rose 6% on Tuesday . The company traded as high as $9.93 and last traded at $9.91. Approximately 313,319 shares were traded during trading, a decline of 61% from the average daily volume of 809,787 shares. The stock had previously closed at $9.35.

Analysts Set New Price Targets

Several brokerages have issued reports on ATXS. Oppenheimer decreased their target price on shares of Astria Therapeutics from $29.00 to $25.00 and set an “outperform” rating for the company in a report on Tuesday, May 21st. Jefferies Financial Group increased their target price on Astria Therapeutics from $22.00 to $27.00 and gave the company a “buy” rating in a research note on Monday, March 25th. HC Wainwright restated a “buy” rating and issued a $16.00 price target on shares of Astria Therapeutics in a research note on Friday, May 10th. Finally, Wedbush reaffirmed an “outperform” rating and set a $22.00 price target on shares of Astria Therapeutics in a report on Friday, May 10th.

Astria Therapeutics Stock Up 8.0 %

The company has a market cap of $617.74 million, a PE ratio of -4.85 and a beta of 0.74. The company’s fifty day moving average is $9.31 and its 200-day moving average is $10.83.

Astria Therapeutics (NASDAQ:ATXS) last released its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.03). Equities research analysts expect that Astria Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.

Institutional Trading of Astria Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ATXS. RA Capital Management L.P. bought a new stake in shares of Astria Therapeutics during the 1st quarter valued at $62,115,000. Perceptive Advisors LLC grew its holdings in Astria Therapeutics by 82.9% during the fourth quarter. Perceptive Advisors LLC now owns 4,004,070 shares of the biotechnology company’s stock valued at $30,751,000 after purchasing an additional 1,814,608 shares during the period. Armistice Capital LLC purchased a new stake in Astria Therapeutics in the fourth quarter worth about $12,119,000. Artal Group S.A. bought a new position in shares of Astria Therapeutics in the first quarter worth about $12,445,000. Finally, Vivo Capital LLC lifted its position in shares of Astria Therapeutics by 47.7% during the 4th quarter. Vivo Capital LLC now owns 2,482,727 shares of the biotechnology company’s stock valued at $19,067,000 after buying an additional 801,528 shares in the last quarter. 98.98% of the stock is owned by hedge funds and other institutional investors.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.